 |
|
Evaluation of Contraceptive Efficacy and Cycle Control of a Transdermal Contraceptive Patch vs an Oral Contraceptive
A Randomized Controlled Trial
Marie-Claude Audet, MD;
Michèle Moreau, MD;
William D. Koltun, MD;
Arthur S. Waldbaum, MD;
Gary Shangold, MD;
Alan C. Fisher, DrPH;
George W. Creasy, MD;
for the ORTHO EVRA/EVRA 004 Study Group
JAMA. 2001;285:2347-2354.
Context Oral contraceptive (OC) pills are effective, but poor compliance increases rates of pregnancy during treatment.
Objective To compare the contraceptive efficacy, cycle control, compliance, and safety of a transdermal contraceptive patch and an OC.
Design Randomized, open-label, parallel-group trial conducted October 1997 to June 1999.
Setting Forty-five clinics in the United States and Canada.
Participants A total of 1417 healthy adult women of child-bearing potential.
Interventions Participants were randomly assigned to receive a transdermal contraceptive patch (n = 812) vs an OC (n = 605) for 6 or 13 cycles. Patch treatment consisted of application of 3 consecutive 7-day patches followed by 1 patch-free week.
Main Outcome Measures Overall and method-failure Pearl Indexes (number of pregnancies/100 person-years of use) and life-table estimates of the probability of pregnancy were calculated. Cycle control, compliance, patch adhesion, and adverse events were also assessed.
Results Overall and method-failure Pearl Indexes were numerically lower with the patch (1.24 and 0.99, respectively) vs the OC (2.18 and 1.25, respectively); this difference was not statistically significant (P = .57 and .80, respectively). The incidence of breakthrough bleeding and/or spotting was significantly higher only in the first 2 cycles in the patch group, but the incidence of breakthrough bleeding alone was comparable between treatments in all cycles. The mean proportion of participants' cycles with perfect compliance was 88.2% (811 total participants, 5141 total cycles) with the patch and 77.7% (605 total participants, 4134 total cycles) with the OC (P < .001). Only 1.8% (300/16 673) of patches completely detached. Both treatments were similarly well tolerated; however, application site reactions, breast discomfort, and dysmenorrhea were significantly more common in the patch group.
Conclusion The contraceptive patch is comparable to a combination OC in contraceptive efficacy and cycle control. Compliance was better with the weekly contraceptive patch than with the OC.
Author Affiliations: Centre Médical des Halles de Ste-Foy, Ste-Foy, Quebec (Dr Audet); Departement d'obstetrique-gynecologie, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec (Dr Moreau); Medical Center for Women's Clinical Research, San Diego, Calif (Dr Koltun); Department of Clinical Research, The R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ (Drs Shangold, Fisher, and Creasy). Dr Waldbaum is in private practice in Denver, Colo.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLE
May 9, 2001
JAMA. 2001;285(18):2393-2394.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Obesity and Oral Contraceptive Failure: Findings from the 2002 National Survey of Family Growth
Brunner Huber and Toth
Am J Epidemiol 2007;166:1306-1311.
ABSTRACT
| FULL TEXT
Contraception and Adolescents
Committee on Adolescence
Pediatrics 2007;120:1135-1148.
ABSTRACT
| FULL TEXT
Rationale for transdermal drug administration in Alzheimer disease
Oertel et al.
Neurology 2007;69:S4-S9.
ABSTRACT
| FULL TEXT
Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease
Blesa et al.
Neurology 2007;69:S23-S28.
ABSTRACT
| FULL TEXT
Polyvinyl Alcohol--Gelatin Patches of Salicylic Acid: Preparation, Characterization and Drug Release Studies
Pal et al.
J Biomater Appl 2006;21:75-91.
ABSTRACT
Hormonal Contraception Update
David et al.
Mayo Clin Proc. 2006;81:949-955.
ABSTRACT
| FULL TEXT
Advances in the management of endometriosis: an update for clinicians
Crosignani et al.
Hum Reprod Update 2006;12:179-189.
ABSTRACT
| FULL TEXT
Intramuscular Testosterone Enanthate Plus Very Low Dosage Oral Levonorgestrel Suppresses Spermatogenesis Without Causing Weight Gain in Normal Young Men: A Randomized Clinical Trial
Anawalt et al.
J Androl 2005;26:405-413.
ABSTRACT
| FULL TEXT
Recent Advances in Hormonal and Barrier Contraception
Raney and Methot
Journal of Pharmacy Practice 2003;16:209-217.
ABSTRACT
Two New Approaches to Hormonal Contraception for Women: Patches and Vaginal Rings
JWatch Women's Health 2001;2001:10-10.
FULL TEXT
Two New Approaches to Hormonal Contraception for Women: Patches and Vaginal Rings
JWatch General 2001;2001:1-1.
FULL TEXT
|
